Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RHHBF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RHHBF and 80,000+ other tickers.
See exactly how RHHBF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RHHBF and 80,000+ other tickers.
Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG is a global enterprise active in both the pharmaceutical and diagnostics sectors. Its extensive operations cover numerous countries, including Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside other international markets. The company's pharmaceutical division develops and provides therapies addressing a broad spectrum of medical conditions. These include cancer (oncology), neurological disorders, infectious diseases, immunological conditions…
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify symptoms related to Alzheimer's disease in patients over age 55, Roche said on Monday morning.
The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed by Roche and Eli Lilly.
The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.
Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference.
Roche Holding AG remains a respectable long-term hold, supported by a deep pipeline, strong execution, and robust financial resources. Q2 results showed 5% revenue growth and better-than-expected operating margin, validating management's focus on R&D efficiency and cost control. Key upcoming clinical readouts in oncology, immunology, and hematology could drive meaningful revenue shifts over the next 12–24 months.